Research Article|Articles in Press

Individualized dosing of evinacumab is predicted to yield reductions in drug expenses

Open AccessPublished:March 14, 2023DOI:


      • Dose optimization of evinacumab may be used to reduce drug expenses.
      • An average 34% dose reduction might be possible without compromising efficacy.
      • This strategy may facilitate access to treatment of evinacumab by reducing costs.


      Evinacumab is a first-in-class inhibitor of angiopoietin‐like protein 3 (ANGPTL3) for treatment of the rare disease homozygous familial hypercholesterolemia (HoFH). With projected drug costs of $450,000 per person per year, the question rises if cost-efficacy of evinacumab can be further improved.


      To develop an individualized dosing regimen te reduce drug expenses.


      Using the clinical and pharmacological data as provided by the license holder, we developed an alternative dosing regimen in silico based on the principles of reduction of wastage by dosing based on weight bands rather than a linear milligram per kilogram body weight (mg/kg) dosing regimen, as well as dose individualization guided by low density lipoprotein cholesterol (LDL-C) response.


      We found that the average quantity of drug used for a dose could be reduced by 34% without predicted loss in efficacy (LDL-C reduction 24 weeks after treatment initiation).


      Dose reductions without compromising efficacy seem feasible. We call for implementation and prospective evaluation of this strategy to reduce treatment costs of HoFH.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nohara A
        • Tada H
        • Ogura M
        • et al.
        Homozygous familial hypercholesterolemia.
        J Atheroscler Thromb. 2021; : RV17050
        • Stefanutti C
        • Julius U
        • Watts GF
        • et al.
        Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs.
        J Clin Lipidol. 2017; 11 (e853): 858-871
        • D'erasmo L
        • Gallo A
        • Cefalù AB
        • et al.
        Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey.
        Orphanet J Rare Dis. 2021; 16: 1-12
        • Wang A
        • Richhariya A
        • Gandra SR
        • et al.
        Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia.
        J Am Heart Assoc. 2016; 5e003294
        • Kuehn BM.
        Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag.
        Circulation. 2021; 143: 2494-2496
        • Pu X
        • Sale M
        • Yang F
        • Zhang Y
        • Davis JD
        • Al-Huniti N
        Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia.
        CPT. 2021; 10: 1412-1421
        • Raal FJ
        • Rosenson RS
        • Reeskamp LF
        • et al.
        Evinacumab for homozygous familial hypercholesterolemia.
        N Engl J Med. 2020; 383: 711-720
        • Raal FJ
        • Rosenson RS
        • Reeskamp LF
        • et al.
        The effect of evinacumab on apheresis eligibility in patients with homozygous familial hypercholesterolemia.
        Circulation. 2020; 142 (A14270-A14270)
      1. Regeneron Information for Colorado Prescribers Provided Pursuant to Colorado House Bill 19-1131 - EVKEEZA® (evinacumab-dgnb) Injection wholesale acquisition cost

        • Zimmermann BM
        • Eichinger J
        • Baumgartner MR.
        A systematic review of moral reasons on orphan drug reimbursement.
        Orphanet J Rare Dis. 2021; 16: 1-21
      2. Fda Evkeeza highlights of the prescribing information

        • Bai S
        • Jorga K
        • Xin Y
        • et al.
        A guide to rational dosing of monoclonal antibodies.
        Clin Pharmacokinet. 2012; 51: 119-135
      3. FDA Drug Approval Package: EVKEEZA

      4. FDA pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer

        • Rosenson RS
        • Burgess LJ
        • Ebenbichler CF
        • et al.
        Evinacumab in patients with refractory hypercholesterolemia.
        N Engl J Med. 2020; 383: 2307-2319